معرفی
Dr. Paul Donaghy is a researcher at Newcastle University, specializing in neurodegenerative diseases, particularly dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD). His work focuses on biomarkers, clinical features, and imaging techniques to differentiate between neurodegenerative disorders. He has contributed to studies analyzing brain connectivity, atrophy patterns, and plasma biomarkers to improve diagnostic accuracy and predict disease progression.
Key research interests include neuropsychiatric symptoms in prodromal DLB, longitudinal clinical outcomes in mild cognitive impairment (MCI), and the role of multimorbidity in neuropathology. His studies often utilize advanced neuroimaging (e.g., MRI, PET) and biomarker profiling to uncover disease mechanisms. Collaborative projects with clinicians and researchers aim to translate findings into clinical practice, such as developing diagnostic criteria and improving patient management strategies.
Dr. Donaghy’s work has addressed challenges in distinguishing DLB from AD, exploring topics like cardiac innervation scintigraphy, cholinergic system degeneration, and polygenic risk factors. He has also investigated the impact of the pandemic on dementia patients and their caregivers, highlighting social inclusion challenges and digital technology applications.
